Biovica's CEO and main shareholder Anders Rylander has, to facilitate the administration of the company's warrant program 3, lent 127,000 shares to Pareto Securities AB.

The program comprises 200,000 options, of which 145,000 options have been transferred. An option gives the right to subscribe for one share for SEK 20.93 and the subscription period runs through August 25, 2021. The transaction has today been registered in Finansinspektionen's register for insider trading.
The shares will be returned when Biovica has issued new shares and the new share issue has been registered with the Swedish Companies Registration Office (Bolagsverket).

Contact

Anders Rylander, CEO
Phone: +46-18-444 48 35
E-mail: anders.rylander@biovica.com

Biovica – Treatment decisions with greater confidence

Biovica develops and commercializes blood-based biomarker assays to evaluate efficacy of cancer treatments. Biovica’s assay DiviTum® measure cell proliferation by detecting a biomarker in the blood stream. The assay has successfully demonstrated its capabilities to early evaluate therapy effectiveness in several clinical trials. The first application for DiviTum is monitoring of treatment for patients with metastatic breast cancer. Biovica's vision is that all cancer patients will get an optimal treatment from day one. Biovica collaborates with world-leading cancer institutes and pharmaceutical companies. DiviTum is CE-marked and registered with the Swedish Medical Products Agency. Biovica's shares are traded on the Nasdaq First North Growth Market (BIOVIC B). FNCA Sweden AB is the company's Certified Adviser, info@fnca.se, +46 8 528 00 399. For more information please visit: www.biovica.com.

Attachments

Biovica's CEO and main shareholder lends shares for redemption of option program

© Modular Finance, source Nordic Press Releases